In a small retrospective study evaluating 25 patients with BRAF-mutant melanoma, the treatment with immunotherapy after a BRAF inhibitor resulted in higher ORR, compared to giving immunotherapy before a BRAF inhibitor (43.8% vs. 0%). Here, BRAF is linked to melanoma.